drugset / Trial / NCT05060588

Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction

NCT05060588

Phase 4 Unknown 200 enrolled Qingdao Central Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Studies have demonstrated that the early initiation of ACEI/ARB to patients with acute myocardial infarction is beneficial, especially in patients combined with reduced LVEF or mild-moderate heart failure. Therefore, ACEI/ARB is a traditional treatment for patients post-infarction. Recent clinical trials have demonstrated that Sacubitril/Valsartan is more beneficial than Ramipril to patients post-PCI.Besides, Sacubitril/Valsartan is also effective for essential hypertension.This study aims to assess the effect of Sacubitril/Valsartan on short-term prognosis in hypertensive patients with acute myocardial infarction compared against Valsartan.

Timeline

Start
2021-10
Primary completion
2022-10
Completion
2023-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Sacubitril/Valsartan Unknown 24 mg
Subject Sacubitril/Valsartan Unknown 26 mg
Comparator Valsartan Small molecule 80 mg